Proprietary Administration
In addition to strategically selecting development compounds with strong potential for clinical success, MacuSight also focuses its efforts on pairing these compounds with optimal approaches to administration. To this end, the company leverages minimally-invasive, sustained, local delivery methods in order to provide its product candidates with significant competitive advantages.
- Local Delivery: Simple periocular injections, such as those used by MacuSight, ensure that drug is delivered and reaches desired concentrations in the targeted area of the eye while minimizing systemic exposure. These are important benefits that position local drug delivery for the treatment of ocular disease as a superior option compared to systemic oral or intravenous administration.
- Minimally-Invasive Administration: By designing therapeutic product candidates that will be administered by simple periocular injections under the conjunctiva and adjacent to the white of the eye (sclera), instead of other areas of the eye (e.g., into the vitreous or behind the eye), MacuSight can offer patients and physicians a simple and much less invasive procedure. Simple periocular injections of this type, which are well-established with physicians, minimize the risk of serious infection and other vision-threatening complications that are associated with intravitreal injections. Periocular injections are also less time consuming and much easier for both patients and physicians.
- Sustained Delivery: Using MacuSight's proprietary formulations to sustain drug within the eye enables extended durations of therapy following a single dose administration. This will allow patients to receive treatment less frequently than required with other ophthalmic therapeutics. As a result, office visits and drug administration costs may be significantly reduced. This is particularly important for chronic diseases and conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
- Potential for Disease Prevention: Less frequent and less invasive administration are two essential characteristics for any therapy to be used in the prevention of diseases such as wet AMD. This is true because more invasive injection procedures possess unacceptable risk profiles for preventive application and require frequent physician visits that are impractical for long-term prevention. Topical eye drops are also inadequate, as they present major convenience and compliance issues, particularly for the elderly population at risk for wet AMD.
|
